These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 20227819)
1. Re: Richard J. Sylvester, Maurizio A. Brausi, Wim J. Kirkels, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73. Cai T; Luciani LG; Malossini G Eur Urol; 2010 Jun; 57(6):e57; author reply e58-9. PubMed ID: 20227819 [No Abstract] [Full Text] [Related]
2. Words of wisdom. Re: Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Lamm DL Eur Urol; 2011 Jun; 59(6):1065. PubMed ID: 21531192 [No Abstract] [Full Text] [Related]
3. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM; Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729 [TBL] [Abstract][Full Text] [Related]
4. Re: Willem Oosterlinck, Ziya Kirkali,Richard Sylvester, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: results of an EORTCGenito-urinary Group Randomized Phase 2 Trial (30993). Eur Urol 2011;59:438-46. Ooi WL; Stockler M; Hayne D Eur Urol; 2011 Jul; 60(1):e1; author reply e2-3. PubMed ID: 21489685 [No Abstract] [Full Text] [Related]
5. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911. Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466 [TBL] [Abstract][Full Text] [Related]
6. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organization for Research and Treatment of Cancer genito-urinary group randomized phase III trial. van der Meijden AP; Brausi M; Zambon V; Kirkels W; de Balincourt C; Sylvester R; J Urol; 2001 Aug; 166(2):476-81. PubMed ID: 11458050 [TBL] [Abstract][Full Text] [Related]
7. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56. Lamm D; Böhle A; Palou J; Persad R; Brausi M; Colombel M; Akaza H; Buckley R Eur Urol; 2010 Feb; 57(2):e7-9; author reply e10-1. PubMed ID: 19914768 [No Abstract] [Full Text] [Related]
8. Can early single dose instillation of epirubicin improve bacillus Calmette-Guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study. Cai T; Nesi G; Tinacci G; Zini E; Mondaini N; Boddi V; Mazzoli S; Bartoletti R J Urol; 2008 Jul; 180(1):110-5. PubMed ID: 18485394 [TBL] [Abstract][Full Text] [Related]
9. Re: Per-Uno Malmström, Richard J. Sylvester, David E. Crawford, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247-56. Aldemir M; Canda AE; Balbay MD Eur Urol; 2010 Aug; 58(2):e23; author reply e24-5. PubMed ID: 20542629 [No Abstract] [Full Text] [Related]
10. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study. Ali-El-Dein B; Nabeeh A; Ismail EH; Ghoneim MA J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034 [TBL] [Abstract][Full Text] [Related]
11. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906). de Reijke TM; Kurth KH; Sylvester RJ; Hall RR; Brausi M; van de Beek K; Landsoght KE; Carpentier P; J Urol; 2005 Feb; 173(2):405-9. PubMed ID: 15643181 [TBL] [Abstract][Full Text] [Related]
12. Re: Can early single dose instillation of epirubicin improve bacillus calmette-guerin efficacy in patients with nonmuscle invasive high risk bladder cancer? Results from a prospective, randomized, double-blind controlled study: T. Cai, G. Nesi, G. Tinacci, E. Zini, N. Mondaini, v. Boddi, s. Mazzoli and R. Bartoletti J Urol 2008; 180: 110-115. Sylvester RJ; Oosterlinck W; O'Donnell M J Urol; 2009 Jan; 181(1):410. PubMed ID: 19010500 [No Abstract] [Full Text] [Related]
13. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer. Witjes JA; Caris CT; Mungan NA; Debruyne FM; Witjes WP J Urol; 1998 Nov; 160(5):1668-71; discussion 1671-2. PubMed ID: 9783928 [TBL] [Abstract][Full Text] [Related]
14. Effect of intravesical instillation on performance of uCYT+ test. Lodde M; Mian C; Negri G; Vittadello F; Comploj E; Palermo S; Staffler A; Brössner C; Pycha A Urology; 2004 May; 63(5):878-81. PubMed ID: 15134970 [TBL] [Abstract][Full Text] [Related]
15. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906). Mehraban D; Esfahani F J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088 [No Abstract] [Full Text] [Related]
16. Intravesical Bacillus Calmette-Guérin versus epirubicin for Ta and T1 bladder cancer. Shang PF; Kwong J; Wang ZP; Tian J; Jiang L; Yang K; Yue ZJ; Tian JQ Cochrane Database Syst Rev; 2011 May; (5):CD006885. PubMed ID: 21563157 [TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related]
18. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. Colombel M; Saint F; Chopin D; Malavaud B; Nicolas L; Rischmann P J Urol; 2006 Sep; 176(3):935-9. PubMed ID: 16890660 [TBL] [Abstract][Full Text] [Related]
19. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of intravesical bacillus Calmette-Guerin instillations in steroid treated and immunocompromised patients. Yossepowitch O; Eggener SE; Bochner BH; Donat SM; Herr HW; Dalbagni G J Urol; 2006 Aug; 176(2):482-5. PubMed ID: 16813873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]